Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Dis Esophagus. 2011 Sep;24(7):495-501. doi: 10.1111/j.1442-2050.2010.01173.x. Epub 2011 Feb 10.
Published data on the long-term survival results of patients with localized esophageal carcinoma receiving late course accelerated hyper-fractionated radiotherapy (LCAF RT) versus conventional fractionated radiotherapy (CF RT) are inconclusive. In order to derive a more precise estimation of the both treatment-regimes, a meta-analysis based on systematic review of published articles was performed. A meta-analysis was performed using trials identified through Pubmed and Chinese national knowledge infrastructure. Results in 5-year survival and 5-year local control were collected from randomized trials comparing LCAF RT with CF RT. Review Manager (The Cochrane Collaboration, Oxford, England) and Stata software (Stata Corporation, College Station, TX, USA) were used for data management. A total of 11 trials were involved in this analysis with 572 cases and 567 controls. Our results showed that LCAF RT, compared with CF RT, significantly improved the 5-year survival (odds ratio [OR]= 2.93, 95% confidence interval [CI]: 2.15-4.00, P < 0.00001) and 5-year local control (OR = 3.96, 95% CI: 2.91-5.38, P < 0.00001). LCAF RT was more therapeutically beneficial than CF RT in the localized esophageal carcinoma.
关于接受晚期加速超分割放疗（LCAF RT）与常规分割放疗（CF RT）的局限性食管癌患者的长期生存结果的已有发表数据尚无定论。为了更精确地评估这两种治疗方案，我们对已发表的文章进行了系统评价的基础上进行了荟萃分析。我们通过 Pubmed 和中国国家知识基础设施（CNKI）数据库检索了相关试验，并进行荟萃分析。我们从比较 LCAF RT 与 CF RT 的随机试验中收集了 5 年生存率和 5 年局部控制率的数据。Review Manager（The Cochrane Collaboration，英国牛津）和 Stata 软件（Stata Corporation，美国德克萨斯州 College Station）用于数据管理。共有 11 项试验纳入了这项分析，共 572 例患者和 567 例对照。我们的结果表明，与 CF RT 相比，LCAF RT 显著提高了 5 年生存率（比值比[OR] = 2.93，95%置信区间[CI]：2.15-4.00，P < 0.00001）和 5 年局部控制率（OR = 3.96，95% CI：2.91-5.38，P < 0.00001）。LCAF RT 在局限性食管癌的治疗中比 CF RT 更具疗效。
